Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
CSPC looks for HER2 white space
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Not so fast for AbbVie in SEZ6
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
Pfizer downgrades disitamab again
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
Datroway and Trodelvy's new breast cancer battle
But the Astra/Daiichi ADC stumbles in lung cancer.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
Pfizer trims its pan-KRAS efforts
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
